drugset / Trial / NCT01139021

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

NCT01139021 ↗

Phase 3 Completed 508 enrolled Novartis Vaccines
Non-randomizedParallel-groupOpen-labelPrevention

Summary

One year antibody persistence after the fourth dose boost or two catch-up doses administered starting from 12 months of age and to evaluate the response to a a third dose boost or two catch-up dose starting at 24 months of age.

Timeline

Start
2010-06
Primary completion
2010-11
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject rMenB+OMV NZ Vaccine — —